LANNETT CO INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $340.6M | $478.8M | $545.7M | $655.4M | $174.4M | $155.0M |
| Operating income | −$176.3M | −$237.3M | $19.6M | −$262.3M | $33.3M | $40.7M |
| Net income | −$231.6M | −$363.5M | −$33.4M | −$272.1M | $12.8M | $13.3M |
| Total assets | $484.4M | $683.7M | $1.14B | $1.19B | $1.58B | $1.60B |
| Total liabilities | $735.5M | $711.2M | $833.7M | $853.4M | $976.4M | $1.04B |
| Equity | −$251.1M | −$27.5M | $302.9M | $334.0M | $598.9M | $561.1M |
| EPS (diluted) | $-5.74 | $-9.23 | $-0.86 | $-7.20 | $0.33 | $0.35 |
| Shares out. | 43.0M | 42.3M | 40.2M | 40.4M | 38.9M | 37.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −51.8%
- Net margin
- −68.0%
- Return on equity
- 92.3%
- Return on assets
- −47.8%
- Return on capital (ROCE)
- −46.4%
- Liabilities / assets
- 151.8%
- Debt / equity
- —
- Book value / share
- $-5.84
- Revenue growth (YoY)
- −28.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -4.31distress
- Accruals / assets
- −46.3%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- HYDROMORPHONE HYDROCHLORIDEDec 9, 2009
- DANAZOLApr 19, 2007
- CLINDAMYCIN HYDROCHLORIDEAug 12, 2005
- FLUPHENAZINE HYDROCHLORIDEAug 25, 1988
- LANIAZIDFeb 3, 1986
- AMPHETAMINE SULFATEAug 31, 1984
- PHENTERMINE HYDROCHLORIDEFeb 3, 1983
- METHYLTESTOSTERONENov 5, 1982
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Chapman John CDirector | Nov 17, 2022 | Buy | 20,000 | $0.51 |
| Lepore Patrick GDirector | Nov 10, 2022 | Buy | 100,000 | $0.49 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Bankruptcy or receivership · New financial obligation · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventJun 20, 2023
- Bankruptcy or receivershipJun 13, 2023
- Bankruptcy or receivership · Debt acceleration / triggering event · Regulation FD disclosureMay 3, 2023
- Terminated a material agreement · Regulation FD disclosureMay 2, 2023
- Entered a material agreement · Director / officer change · Regulation FD disclosureMay 1, 2023
- Delisting / listing-standard notice · Regulation FD disclosure · Other material eventApr 20, 2023
- Director / officer changeApr 14, 2023
- Other material eventApr 4, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.